Use of somatostatin agonists in the treatment of SSTR3-expressing tumors

JP2025500500A5Pending Publication Date: 2025-10-31ITALFARMACO SPA
0 Cites 0 Cited by

Patent Information

Application Number
JP2024538373
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-24
Filing Date
2022-12-22
Publication Date
2025-10-31

AI Technical Summary

Technical Problem

Current treatments for non-functioning pituitary adenomas (NFPA) are inadequate, with high regrowth rates and limited effectiveness of existing drug therapies, and there is a need for new drug therapies with low side effects for NFPA and other neuroendocrine-related malignancies.

Method used

Development of a novel cyclic somatostatin analogue, ITF2984, which exhibits high affinity for SSTR3 receptors, leading to effective inhibition of tumor growth and proliferation by inducing receptor internalization and phosphorylation, and is administered in combination with other active principles to enhance therapeutic efficacy.

Benefits of technology

ITF2984 demonstrates significant antitumor activity in NFPA models, reducing tumor volume and proliferation, with selective effects in SSTR3-expressing tumors, and is well-tolerated with minimal side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to the use of a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate thereof in the treatment of SSTR3-expressing tumors selected from nonfunctioning pituitary adenomas (NFPAs) or other neuroendocrine-related malignancies selected from pancreatic tumors, pheochromocytoma, paraganglioma, lung carcinoid or breast cancer. More specifically, the present invention provides for the use of a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt and / or solvate thereof, and at least one physiologically acceptable excipient, in the treatment of patients suffering from a SSTR3-expressing tumor selected from a non-functioning pituitary adenoma (NFPA) or other neuroendocrine-related malignancy selected from pancreatic tumor, pheochromocytoma, paraganglioma, lung carcinoid or breast cancer.
Need to check novelty before this filing date? Find Prior Art